News
Discover our latest updates
Higher Medicine Awarded a STEM EDGE Grant by the State of Delaware
Higher Medicine (HMd) and its Delaware subsidiary, HigherTherapeutics (HTx), announced it has been awarded a grant in the Spring 2025 EDGE competition by the Delaware Division of Small Business.
Higher Medicine Establishes Higher Therapeutics to Advance Friedreich’s Ataxia Program
Higher Medicine announces the formation of Higher Therapeutics, a wholly-owned, Delaware-based subsidiary dedicated to developing novel treatments for Friedreich’s ataxia.
Higher Medicine Announces a Pre-Seed Builder Fund Investment from TEDCO
TEDCO's Pre-Seed Builder Fund, one of the state's marquee investment vehicles in Maryland, invested in Higher Medicine.
Higher Medicine Announces Strategic Investment and Clinical Alliance with 5 Horizons Capital to Advance a Clinical Trial
Under the agreement, 5HC has committed to an equity investment valued at $181,492 in support of Higher Medicine’s upcoming Phase 1b/2a clinical trial in a rare pediatric disorder.
Higher Medicine Announces Exclusive Option Agreement with Johns Hopkins Technology Ventures for Epigenetic Drug Candidate Screening Technology
Higher Medicine has entered into an exclusive option agreement with Johns Hopkins Technology Ventures (JHTV) to advance development of a proprietary histone reporter allele platform for epigenetic drug discovery.
Higher Medicine Joins BIO 2025 in Boston as a part of the Maryland Delegation
Higher Medicine attends the 2025 BIO International Convention from June 16–19 in Boston, MA, as part of the official Maryland delegation.